TY - JOUR
T1 - Design principles of ocular drug delivery systems
T2 - importance of drug payload, release rate, and material properties
AU - Subrizi, Astrid
AU - Amo, Eva M Del
AU - Korzhakov-Vlakh, Viktor
AU - Tennikova, Tatiana
AU - Ruponen, Marika
AU - Urtti, Arto
N1 - Copyright © 2019. Published by Elsevier Ltd.
PY - 2019
Y1 - 2019
N2 - Ocular drugs are usually delivered locally to the eye. Required drug loading, release rate, and ocular retention time of drug delivery systems depend on the potency, bioavailability, and clearance of the drug at the target site. Drug-loading capacity of the formulation is limited by the material properties and size constraints of the eye. The design aid described herein for ocular drug delivery systems guides the calculation of steady-state drug concentrations in the ocular compartments, taking into account drug dose, bioavailability, and clearance. The dosing rate can be adjusted to reach the target drug concentrations, thereby guiding the design of drug delivery systems for topical, intravitreal, and subconjunctival administration. The simple design aid can be used at early stages of drug development by investigators without expertise in pharmacokinetic and pharmacodynamic modeling.
AB - Ocular drugs are usually delivered locally to the eye. Required drug loading, release rate, and ocular retention time of drug delivery systems depend on the potency, bioavailability, and clearance of the drug at the target site. Drug-loading capacity of the formulation is limited by the material properties and size constraints of the eye. The design aid described herein for ocular drug delivery systems guides the calculation of steady-state drug concentrations in the ocular compartments, taking into account drug dose, bioavailability, and clearance. The dosing rate can be adjusted to reach the target drug concentrations, thereby guiding the design of drug delivery systems for topical, intravitreal, and subconjunctival administration. The simple design aid can be used at early stages of drug development by investigators without expertise in pharmacokinetic and pharmacodynamic modeling.
UR - https://www.scopus.com/pages/publications/85061607596
U2 - 10.1016/j.drudis.2019.02.001
DO - 10.1016/j.drudis.2019.02.001
M3 - Article
C2 - 30738982
SN - 1359-6446
JO - Drug discovery today
JF - Drug discovery today
ER -